Relia Tech/Mouse CD105/Endoglin, soluble/5 µg/S01-022
市场价：
¥1500.00
美元价：
900.00
产品分类：
细胞代谢
公司分类：
cellular_metabolism
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | S01-022 |
| Size | 5 µg |
| Price | 75 € |
| Source | Insect cells |
| Label | His-Tag |
| Formulation | lyophilized |
| Purity Confirmation | > 90% by SDS-PAGE |
| Length [aa] | 558 |
| Molecular Weight | 70-75 kDa |
| Biological Activity | Testing in Progress. |
| Species Reactivity | Mouse |
| Buffer | PBS |
| Reconstitution | The lyophilized sCD105 is soluble in water and most aqueous buffers and should be reconstituted in PBS or medium to a concentration not lower than 50µg/ml. |
| Stability and Storage | Lyophilized samples are stable for greater than six months at -20°C to -70°C. Reconstituted sCD105 should be stored in working aliquots at -20°C. |
| Synonyms | Eng; CD105; AI528660; AI662476; S-endoglin |
| Description | A DNA sequence encoding the extracellular domain of mouse Endoglin (Met 1 - Gly 581) was expressed in insect cells. Mouse Endoglin is a disulfide-linked homodimeric protein. Based on N-terminal sequence analysis, the primary structure of recombinant mature Endoglin starts at Glu 26. Endoglin has a calculated monomeric molecular mass of 61 kDa but as a result of glycosylation, migrates at approximately 75 - 85 kDa under reducing conditions in SDS-PAGE. Endoglin, also known as CD105, is a Type I integral membrane glycoprotein with a large, disulfide-linked, extracellular region and a short, constitutively phosphorylated, cytoplasmic tail. Two splice variants of human endoglin, the S-endoglin and L-endoglin that differ in the length of their cytoplasmic tails have been identified. Endoglin is highly expressed on vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta. It is also found on activated monocytes, bone marrow pro-erythroblasts, and leukemic cells of lymphoid and myeloid lineages. Human and mouse endoglin share approximately 70% and 97 % amino acid sequence identity in their extracellular and intracellular domains, respectively. In common with betaglycan (also named TßRIII), a proteoglycan that shares regions of sequence similarity, endoglin is an accessory receptor for the TGF- superfamily ligands. Endoglin does not bind ligands by itself, but does so by associating with a ligand-binding serine/threonine kinase receptor. Endoglin binds TGF-1 and TGF-3 but not TGF-2 efficiently by associating with TGF- type II receptor (TßRII). It interacts with activin-A and BMP-7 using either the activin type II or type IIB receptors. In the case of BMP-2 which binds directly to the type I but not the type II BMP receptor, endoglin binds via either BMPR-IA (ALK-3) or BMPR-1B (ALK-6). Although the consequence of endoglin interactions on the functions of TGF- family ligands is poorly understood, endoglin has clearly been shown to be required for angiogenesis and to play a key role in heart development. Mutations in human endoglin or ALK-1 (another type I serine/threonine receptor) lead to the vascular disorder hereditary hemorrhagic telangiectasia (HHT). Mice heterozygous for endoglin have been developed as disease models for HHT. Endoglin has been shown to be a powerful marker of neovascularization. It is also useful as a functional marker that defines long-term repopulating hematopoietic stem cells. |
| Protein Sequence | ERVGCDLQPVDPTRGEVTFTTSQVSEGCVAQAANAVREVHVLFLDFPGMLSHLELTLQASKQNGTETQEVFLVLVSNKNVFVKFQAPEIPLHLAYDSSLVIFQGQPRVNITVLPSLTSRKQILDWAATKGAITSIAALDDPQSIVLQLGQDPKAPFLCLPEAHKDMGATLEWQPRAQTPVQSCRLEGVSGHKEAYILRILPGSEAGPRTVTVMMELSCTSGDAILILHGPPYVSWFIDINHSMQILTTGEYSVKIFPGSKDKGVELPDTPQGLIAEARKLNASIVTSFVELPLVSNVSLRASSCGGVFQTTPAPVVTTPPKDTCSPVLLMSLIQPKCGNQVMTLALNKKHVQTLQCTITGLTFWDSSCQAEDTDDHLVLSSAYSSCGMKVTAHVVSNEVIISFPSGSPPLRKKVQCIDMDSLSFQLGLYLSPHFLQASNTIELGQQAFVQVSVSPLTSEVTVQLDSCHLDLGPEGDMVELIQSRTAKGSCVTLLSPSPEGDPRFSFLLRVYMVPTPTAGTLSCNLALRPSTLSQEVYKTVSMRLNIVSPDLSHHHHHH |
| Uniprot ID | Q63961 |
| Protein RefSeq | NP_031958 |
| mRNA RefSeq | NM_007932 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
